[Editor's Note: A version of this article originally appeared in In Vivo on 11 August.]
Investment activity in biopharma, healthtech, diagnostics and medtech in the first half of 2022 had to be assessed against the...
European Healthtech Grabs The Investor Headlines In H1 2022
Cautious Optimism For Sector And M&A Set To Stay Strong In 2022
After a runaway 2021 and a strong if bumpy first quarter of 2022, all health care product sectors underwent an investment dip in the second quarter, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.
More from Diagnostics
More from Device Area
• By
Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.
• By
A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.
• By
CMS is proposing to classify all CGMs and insulin pumps as “items requiring frequent and substantial servicing” to expand device choice and access for Medicare beneficiaries. Under this framework, CMS also intends to move Class II devices, which include CGMs from Abbott and Dexcom and pumps from Tan